Y Wu: presenting SANOVO trial. Number of patients screened is enormous. Significant PFS 24 months vs 11.1 months and OS benefit HR 0.48! Minimal increase in AEs. Note increased MET has much worse PFS to what we usually see with Osi. Impressive results. #LCSM #ESMO26